GD2 CAR-T Cells in Combination with Nivolumab Exhibit Enhanced Antitumor Efficacy

A combined therapeutic strategy was tested in the current study using GD2 CAR T together with Nivolumab, an anti-PD-1 monoclonal antibody. Animal studies suggested that GD2 CAR T effectively infiltrated into tumor tissue and significantly hampered tumor progression.